Skip to content

Efficacy and Safety of Berberista Powder for Blood Glucose Management

Efficacy and Safety of BerberistaTM for the Management of High Blood Glucose - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109397
Enrollment
20
Registered
2026-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Berberista powder: Berberista powder 500 mg twice a day for 60 days Control Intervention1: NA: NA

Sponsors

M R HEALTHCARE PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex between the age group 18 to 65 years; Patients who are diagnosed with high blood glucose; Subjects with Body Mass Index between 27 to 45; Women of childbearing potential must be willing to use double-barrier contraception for the entire study; Patients ready to abide by trial procedures and to give informed consent

Exclusion criteria

Exclusion criteria: Subjects with Type 1 diabetes mellitus, severe hyperglycemia, fasting serum cholesterol and serum Triglycerides; Subjects with BMI more than 45 and HbA1c more than 10.5; Subjects with severe renal, hepatic or respiratory disorder; Subjects with psychiatric, and hematological disorders; Subjects with Ischemic heart disease with any cardiac event in last 6 months; Participants who have participated in any investigational study; Patients having known hypersensitivity to the study drugs; Patients with a history of intake of any Ayurveda, herbal, homeopathic, dietary supplements or any alternative therapies; Pregnant or lactating females and women in child bearing age refusing to use of contraceptive methods

Design outcomes

Primary

MeasureTime frame
Change in fasting and postprandial blood glucose levels from screening to end of study (Day 60)Timepoint: Change in fasting and postprandial blood glucose levels from screening to end of study (Day 60)

Secondary

MeasureTime frame
Change in body weight; BMI; waist circumference; Complete Blood Count (CBC); Liver Function Test (SGOT); Renal Function Test (Creatinine); Total Cholesterol and Triglycerides; clinical symptom scores; Incidence and severity of adverse eventsTimepoint: Screening and Day 60

Countries

India

Contacts

Public ContactMr Manik Chaudhuri

BIORADIAN LIFESCIENCE

amal.bioradian@gmail.com8697612674

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026